Anika Therapeutics, Inc. Acquisitions, Net of Cash Acquired
Anika Therapeutics, Inc. (ANIK) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2024-03-15
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2021 was $476.00K, a 99.50% decline from fiscal 2020.
- Anika Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2020 was $94.60M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-15 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 10-K · filed 2024-03-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $113.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $113.00K derived: sum of 3 quarters · filed 2024-03-15 | $124.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $113.00K derived: sum of 2 quarters · filed 2024-03-15 | $124.00K derived: sum of 3 quarters · filed 2024-03-15 | $126.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $124.00K derived: sum of 2 quarters · filed 2024-03-15 | $126.00K derived: sum of 3 quarters · filed 2024-03-15 | $476.00K 10-K · filed 2024-03-15 |
| 2021-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $13.00K derived: sum of 2 quarters · filed 2022-11-09 | $363.00K 10-Q · filed 2022-11-09 | $1.10M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $352.00K 10-Q · filed 2022-08-04 | $1.09M derived: sum of 3 quarters · filed 2023-03-16 | $1.09M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $350.00K 10-Q · filed 2022-05-06 | $1.09M derived: sum of 2 quarters · filed 2023-03-16 | $1.09M derived: sum of 3 quarters · filed 2023-03-16 | $1.97M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $742.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $742.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.62M derived: sum of 3 quarters · filed 2023-03-16 | $94.60M 10-K · filed 2023-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $876.00K derived: sum of 2 quarters · filed 2021-11-05 | $93.86M 10-Q · filed 2021-11-05 | $93.86M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $876.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $93.86M 10-Q · filed 2021-08-06 | $93.86M derived: sum of 3 quarters · filed 2022-03-11 | $93.86M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $92.98M 10-Q · filed 2021-05-07 | $92.98M derived: sum of 2 quarters · filed 2022-03-11 | $92.98M derived: sum of 3 quarters · filed 2022-03-11 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 10-K/A · filed 2021-04-26 | |||
| 2009-12-31 | $16.26M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |